<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05079165</url>
  </required_header>
  <id_info>
    <org_study_id>8261</org_study_id>
    <nct_id>NCT05079165</nct_id>
  </id_info>
  <brief_title>Covid Vaccination in Liver Transplantation</brief_title>
  <acronym>VACCHEPA</acronym>
  <official_title>EVALUATION OF THE RESPONSE TO mRNA SARS-CoV-2 VACCINE IN A COHORT OF LIVER TRANSPLANTED OR LISTED PATIENTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this retrospective study is to evaluate the proportion of seroconversion after 2&#xD;
      doses mRNA anti-SARS-CoV2 vaccination in a cohort of high risk liver transplanted patients.&#xD;
&#xD;
      Seroprevalence is a secondary objective in order to identify seronegative patients with a&#xD;
      history of COVID-19 (ie who lost antibodies) and seropositive patients with no history of&#xD;
      COVID-19.&#xD;
&#xD;
      The hypothesis is that the degree of immunosuppression is determinant on the seroconversion&#xD;
      rate and therefore, although at higher risk of severe forms of COVID-19, liver transplanted&#xD;
      patients have a lower chance of being protected after vaccination.&#xD;
&#xD;
      Seroconversion rate in previously seronegative and with no history of COVID-19 liver&#xD;
      transplanted patients is the main evaluation criteria.&#xD;
&#xD;
      The factors associated with the absence of seroconversion will be identified as a potential&#xD;
      tool to better adapt the vaccination strategy in this population.&#xD;
&#xD;
      The rate of seroconversion after the 1st dose will also be evaluated. Safety of the 1st and&#xD;
      2nd injection will be reported as well as their value to predict seroconversion.&#xD;
&#xD;
      A control group of patients listed for transplantation will also be included both in the&#xD;
      seroprevalence and the seroconversion analysis.&#xD;
&#xD;
      Persistance of the antibodies in long-term after transplantation and after transplantation&#xD;
      for the patients who have been vaccinated before transplantation will also be reported.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retrospective description of the serological response to the anti-SARS-CoV-2 mRNA vaccine</measure>
    <time_frame>Files analysed retrospectively from January 18, 2020 to April 30, 2021 will be examined]</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>COVID-19</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Liver transplanted adult patients for &gt; 6 months after transplantation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Liver transplanted patients for &gt; 6 months after transplantation&#xD;
&#xD;
          -  Listed cirrhotic patients&#xD;
&#xD;
          -  Age &gt;18 years-old&#xD;
&#xD;
          -  Consent for vaccination with mRNA vaccine&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Vaccination with non mRNA anti-SARS-CoV-2 vaccine&#xD;
&#xD;
          -  Expressed opposition to participation to the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>François FAITOT, MD, PhD</last_name>
    <phone>33 3.88 12 72 85</phone>
    <email>francois.faitot@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saïd CHAYER, PhD, HDR</last_name>
    <email>said.chayer@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service deChirurgie Générale Hépatique-Endocrinienne,et transplantation - Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François FAITOT, MD, PhD</last_name>
      <phone>33 3.88 12 72 85</phone>
      <email>francois.faitot@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Saïd CHAYER, PhD, HDR</last_name>
      <email>said.chayer@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>François FAITOT, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe BACHELLIER, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves HANSMANN, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathilde DERIDDER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry ARTZNER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Baptiste MICHARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samira FAFI-KREMER, PharmD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 14, 2021</study_first_submitted>
  <study_first_submitted_qc>October 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-COV-2</keyword>
  <keyword>Coronavirus Vaccine</keyword>
  <keyword>COVID-19 Pandemic</keyword>
  <keyword>COVID-19 Virus Disease</keyword>
  <keyword>SARS-CoV-2 Infection</keyword>
  <keyword>Solid organ transplant</keyword>
  <keyword>mRNA vaccine</keyword>
  <keyword>MODERNA</keyword>
  <keyword>liver transplant</keyword>
  <keyword>Serological testing</keyword>
  <keyword>serological response</keyword>
  <keyword>SARS-CoV-2 mRNA vaccine</keyword>
  <keyword>Anti-SARS-CoV-2 IgG antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

